ImmuPharma (LON:IMM) Shares Up 27.3% - Here's Why

Key Points

• ImmuPharma's share price increased by 27.3% during trading, reaching GBX 12.60 ($0.17) after closing at GBX 9.90 ($0.13) previously.
• The company has a market capitalization of £63.34 million and a significantly negative price-to-earnings ratio of -1,415.73.
• ImmuPharma is a biopharmaceutical firm focused on peptide-based therapeutics, with its lead program aimed at treating autoimmune diseases such as Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 27.3% during trading on Friday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during mid-day trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Price Performance

The firm has a market cap of £63.34 million, a PE ratio of -1,415.73 and a beta of 1.53. The business's fifty day moving average is GBX 7.92 and its 200-day moving average is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.